The 2026 European Society for Medical Oncology (ESMO) meeting showcased a wave of cutting‑edge cancer research, with 28 late‑breaking abstracts (LBAs) from Chinese institutions stealing the spotlight. Highlights spanned every major tumor type. In head and neck cancer, the OPTIMAL Phase II trial tested peri‑operative tislelizumab combined with chemotherapy for locally advanced, resectable oral squamous‑cell carcinoma, aiming to improve surgical outcomes. Emerging therapies featured GFH276, a novel agent evaluated in patients with previously treated RAS‑mutated solid tumors, and MRG007 (ARR‑217), a CDH17‑directed antibody‑drug conjugate (ADC) tested for the first time in advanced solid cancers. Exploratory immunotherapy presented a personalized neoantigen vaccine paired with precision lesion radiotherapy (CLERT) in the iNATURE Phase II trial, offering a tailored attack on advanced solid tumors. Breast cancer research introduced trastuzumab rezetecan (SHR‑A1811) for HER2‑low disease and anbenitamab plus albumin‑bound docetaxel for HER2‑positive cancers, both in large Phase III studies. Lung cancer saw a HER3‑directed ADC (Ruzaltatug) compared against platinum chemotherapy in EGFR‑mutated non‑small‑cell lung cancer after EGFR‑TKI failure. Melanoma investigators reported extended follow‑up of autologous tumor‑infiltrating lymphocytes (GC101 TIL) in a pivotal Phase II trial. Finally, a head‑to‑head Phase III study (TAISHAN‑301) evaluated tam‑peli versus standard chemotherapy in heavily pre‑treated nasopharyngeal carcinoma. Collectively, these studies underscore China’s growing influence in oncology, delivering novel immunotherapies, targeted agents, and combination strategies that could reshape treatment standards worldwide.
Read moreChinese researchers have unveiled a series of breakthrough studies that put the anti‑androgen drug darolutamide at the center of new, less‑toxic cancer treatments. In a Phase II trial (DISCOVARY), combining darolutamide with the hormone‑blocking agent goserelin gave patients with androgen‑receptor‑positive salivary‑gland carcinoma a chemotherapy‑free option, achieving meaningful tumor control with minimal side‑effects. The same drug proved valuable in prostate cancer. Six months of neoadjuvant darolutamide plus androgen‑deprivation therapy (ADT) before surgery safely shrank locally advanced tumors, while circulating‑tumor‑DNA testing helped predict which patients might relapse. In the large Phase III ARASENS study, adding darolutamide to the standard ADT‑plus‑docetaxel regimen extended overall survival for men with metastatic hormone‑sensitive prostate cancer, without raising adverse‑event rates. Darolutamide also showed activity in a niche breast‑cancer subgroup: patients with triple‑negative, androgen‑receptor‑positive disease experienced a 61 % clinical‑benefit rate versus just 10 % with other tumors. Finally, the ARANOTE trial demonstrated that darolutamide + ADT delayed pain progression and preserved quality of life in metastatic prostate cancer patients, reinforcing its safety profile. Together, these findings suggest darolutamide could become a versatile, chemo‑sparing backbone for several hormone‑driven cancers.
Read more